Clemons, Mark http://orcid.org/0000-0002-0738-2713
Simos, Demetrios
Sienkiewicz, Marta
Ng, Terry
Zibdawi, Labib
Basulaiman, Bassam
Awan, Arif
Fergusson, Dean
Vandermeer, Lisa
Saunders, Deanna
Hutton, Brian
Amir, Eitan
,
Funding for this research was provided by:
Cancer Care Ontario (Clinical Programs and Quality Initiatives grants 2017 and 2018)
Article History
Received: 11 January 2021
Accepted: 8 March 2021
First Online: 19 March 2021
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and the Ontario Cancer Research Ethics Board and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Integrated informed consent was obtained from all trial participants included in the study.
: The participants gave consent to de-identified publication of aggregate study results.
: MC reports personal fees (honoraria) from Pfizer, outside the submitted work. TN reports personal fees (honoraria) from ARIAD, Takeda and Boehringer-Ingelheim, outside the submitted work. AA has participated on an advisory board for Novartis, Eli Lily, Exactis innovation and Pfizer, has received honoraria from Apobiologix and Roche and has received travel funds from Roche. BH reports consulting fees from Cornerstone Research, outside the submitted work. All other authors declare no competing interests.